This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Very good post Mickey,i enjoyed reading that..JB..

How low can this SP go,,did'nt think i'd see it here,,sells now at 126p !!

Thanks Mickey, very good post which let me have a clearer and better concept of the market.

so it could mean MMs got a big buyer, and for last few weeks, MMs tried to lower prices to panic us into selling, in order to fill that big buyer, isn't it? If so, how low the price would gone to be? Until the big buyer get enough?

many thanks
swseun

Its very disappointing to see the sp fall to these levels and the chart looks it could fall even further to 120p..

Previous support levels at 120, 100 and 60.
As this is news driven, it all depends on when the next news is out.

120p is not far at all now

sorry, it's already 120p, lol

This stock is being actively traded at the moment and traders will be aware of the strong support at 120.
These chaps are not greedy or stupid so may well close shorts as we approach the 120 level.

swesun, if the mm's needed to halve it to get stock then they are really taking the piss. As I've said many times, the sp got ahead of itself on the Genvax news and speculation re: Ruthenium and possible deals with big pharmas.
Having said that, I didn't expect to see 120p again!! If the speculation had been followed up with early trials on Ruthenium or a deal the sp would have been much higher, but without news its looks likely to head lower.
If we do see 100p and below as someone else predicted it will be unbelievable, although that would be good for me in terms of buying op and re-entry into MMG I sincerely hope not for the sake of the good folk like you who invested in this at high prices. MMG still has a fantastic portfolio and is potentially very rewarding but learn as I did how this speculative stock trades on news and kills you without it.

Looks like Pete is correct as buyers back in at below 130p, this is a traders share right now, difficult for investors already in or those wanting to get in to guess where the hell this will go. Need some news MMG, that bloody presentation has done nothing to help investors in the short-term. Long-term, if the product portfolio does deliver, investors will have the last laugh.

I'm in at 132p...

andy, you are right, it is very disappointing to see 120p, and now most would expect (even dn't wnat to ) further drop would be in the near further. Even MMG got its fantastic portfolio, if no one realises it, inc. the investors dn't do research, MMs would just take the chance, and let the price down, shake the tree, isn't it?
I have thought to sell and back again, however, I am not very good at that skill. If price grows up, even not to my buying price, I should feel like gainning (i know it sounds ridiculous, but under this situation, I can't help.) But once the "steady growth start, I would buy in again, instead of keep thinking what the bottom price it is. Am I right? Plase let me know your opinion.

many thanks
swseun

swesun, I agree with your point of view, I believe you are new to this lark as I was last year and its best to play the game that you know. For what its worth I would not be selling at 120p in your position, I'd hold and if I got the cash buy lower once I believed it had settled. Doesn't mean I'm right though and it could go down further so its up to you really . IF ONLY, I had not been so ridiculed for suggesting it would fall from 270p to below 200p and there was a chance to trade and buy back later, maybe more would have done what I did but hey, its done now. There was so much hype and enthusiasm that my thoughts were overlooked, I even got stick for delving too far for info re: trial news which whilst justified and I accept that, it was to try and prevent people getting too heavy into MMG because I feared this would happen based upon my experience of the sp. You see, I was trying to help and not shorting, its not my game and I don't have the funds to try it anyway, too risky.

Its fallen form its high of 300p to todays level of 126p.. thats a fall of 62%.. and guess what the fibonnaci full retracement figure is.. you guessed it 61.8%..remarkable.

andy, totally agree with u, it is exactly I mean in my last post. I desided to hold it coz I know it is a good company, and have a bright future. MM is now playing game, but I am not joining in and not panic to sell as well, just hold my share. As righ now, I am out of bullet to buy, so I will wait until the price stable.

Guys I've gone back through the postings and want to try a give everyone some positive thoughts. So I've reposted this. Note the date, it was less than a month ago with a price of 275p. With the exception of the presentation nothing has changed. Andy called this one right warning us but none of us listened. We all got carried away and lost the plot. EK called it right as well. When I took the time to be dispassionate, it became obvious that this was a screaming short. Should the price rise again on nothing substantial then it will remain so. Don't panic and have patience, our day will come and plan you exit point.


goldfinger - 19 Apr'05 - 00:17 - 1302 of 1570

The last but one Insinger note, we know they have now updated to 275p.


Insinger de Beaufort 131 Finsbury Pavement
Tel +44 (0) 20 7190 7000 London
www.insinger.com EC2A 1NT
UK Equity Research 22 February 2005
Trading View
Independent Banking
Source: Insinger de Beaufort, Bloomberg

Accelerating development pipeline

Significant commercial potential: MMI is an emerging biotechnology company
focused in cancer and infectious diseases, both areas of significant commercial
potential. MMIs strategy is to develop drugs to Phase II clinical trial stage and then
commercialise via out-licencing agreements with pharmaceutical companies. Thin
pipelines and patent expiries have acted as a catalyst for a large number of deals
with small cap biotechs such as MMI, even for products which are relatively early
stage. For example a deal with Oxxon Therapeutics could potentially be worth up to
44m in up-front and milestone payments in order to access Xenovas early stage
cancer DISC HSV vector technology. It is also interesting to note recent benchmark
deals for pre clinical early stage compounds with promise - Novartis paid c.$157m to
Xenon and J&J is paying up to $295m in a deal excluding royalties to Arena.
MMI has four R&D divisions:
a) Oncosense (wholly owned) - technology based around the precious metal
ruthenium which is potentially up to 15 times more efficacious than the
most potent platinum anticancer drug.
b) Genvax (JV) - developing DNA vaccines for cancer with Southampton
University/Cancer Research UK Leukaemia Research Fund
c) Viratis (JV) - viral infections with Kings College London
d) Endozyme (wholly owned) - drug resistant Infections working with
Cambridge University/Novartis
MMI also provides technical services to UK academic and commercial institutions
which apart from generating revenues, also provides a stream of potential in -
licensing opportunities.
Tight cost control: Given a current cash balance of 2.6m, MMI has enough cash to
last until Q1 06. Whilst it would not be prudent to discount a future fund raising,
additional cash inflows may come from licensing deals. Furthermore

I still wonder if MMI are pandering to a big pharma regarding Ru.
Why say you are going to clinic within 3 months (at AGM in OCT, DB said RU in clinic late 2004) and then 5 months later you are still not there.
Nothing changed during that time so you have to wonder why.
My guess would be a big pharma stipulated extra tests and have all but agreed a deal pending these further tests.

Put this against a backdrop of late stage failures and setbacks for the big pharmas pipelines and it all seems feasible (IMHO).

These are just my musings based on second guessing and trying to read between the lines of DB's dialogue.

I was wondering why they bought Dr H in at such a late stage in developments it must have been on the insistance of DB that nothing was left to chance when there was a deal in the offing.

Mitzy

When do you think we'll hear some news? Probable a few weeks away yet. Does DB check out the sp regularly. If so he'll know what's going on and hopefully do something about it.

MS
PS Where's GF today?

GF went to bed and will be back at 5 for the election news.